Archives for November 2011

Cetuximab and Chemoradiation Therapy Significantly Improves Overall Survival of Patients with Unresectable Stage III NSCLC

Non-small cell lung cancers (NSCLC) commonly express the epidermal growth factor receptor (EGFR), which is associated with poor clinical outcome. Cetuximab is an inhibitor of EGFR and has radio-sensitization properties. In this study of patients… [Learn More…]

Keeping Abreast Of Breast Cancer

This article was written for and previously published in the Fall 2011 edition of the Women’s magazine Encompass. The article explores some exciting new scientific information on cancer treatment and prevention for women over 50. READ ARTICLE -… [Learn More…]

JX-594 Update: Improved Survival for Patients with Advanced Hepatocellular Carcinoma

In this phase II trial of patients with advanced, previously treated hepatocellular carcinoma (HCC),  52% of patients exhibited disease stabilization. The median overall survival was  13.8 mths with 25% of patients survived 32 mths (to date)…. [Learn More…]